Edgewise Therapeutics, Inc. (EWTX)
45.44
+1.81
(+4.15%)
USD |
NASDAQ |
Sep 16, 16:00
45.99
+0.55
(+1.21%)
After-Hours: 20:00
Edgewise Therapeutics Max Drawdown (5Y) : 84.69% for Aug. 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| August 31, 2026 | 84.69% |
| July 31, 2026 | 84.69% |
| June 30, 2026 | 84.69% |
| May 31, 2026 | 84.69% |
| April 30, 2026 | 84.69% |
| March 31, 2026 | 84.69% |
| February 28, 2026 | 84.69% |
| January 31, 2026 | 84.69% |
| December 31, 2025 | 84.69% |
| Date | Value |
|---|---|
| November 30, 2025 | 84.69% |
| October 31, 2025 | 84.69% |
| September 30, 2025 | 84.69% |
| August 31, 2025 | 84.69% |
| July 31, 2025 | 84.69% |
| June 30, 2025 | 84.69% |
| May 31, 2025 | 84.69% |
| April 30, 2025 | 84.69% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Cocrystal Pharma, Inc. | 97.93% |
| CNBX Pharmaceuticals, Inc. | 100.0% |
| GB Sciences, Inc. | 100.00% |
| Arvinas, Inc. | 94.37% |
| Fulcrum Therapeutics, Inc. | 92.70% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | 14.74 |
| Beta (5Y) | 0.3241 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 79.74% |
| Historical Sharpe Ratio (5Y) | 0.2217 |
| Historical Sortino (5Y) | 0.4933 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 25.70% |